

Manuscript Details

Manuscript number	RVSC_2017_768_R1
Title	Use of urinary gamma-glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with leishmaniasis treated with N-methylglucamine antimoniate
Article type	Research Paper

Abstract

The aim of this study was to assess if the coupled analysis of the urinary protein to creatinine (UPC) ratio and of the GGT/UC ratio (the ratio between urinary gamma-glutamyl transferase activity and urinary creatinine) may be used in treated leishmaniotic dogs to differentiate dogs with transient impairment of tubular function from dogs with persistent tubular damage. To this aim, 40 urine from 10 proteinuric and leishmaniotic dogs that at the first visit had high GGT/UC ratio, consistent with tubular damage, were collected and analyzed before treatments and 2, 4 and 6 weeks after treatment with N-methylglucamine antimoniate and allopurinol. Compared with pre-treatment values, at the end of the study period the UPC ratio decreased only in 5/10 dogs, which, however, were still proteinuric or borderline proteinuric. Conversely, the GGT/UC ratio decreased in 8/10 dogs and in 3 of them the values at the end of the study period were below the threshold consistent with tubular proteinuria. The GGT/UC values at 6 weeks was significantly lower than before treatment. However, transient increases were frequent for both the analytes. These results indicate that in most of the dogs that remain proteinuric after treatment, likely due to the persistent glomerular damage, the GGT/UC ratio tends to normalize. This suggests that in these dogs tubular proteinuria at admission depends on functional impairment of tubular cells likely due to the overflow of proteins from damaged glomeruli. However, tubular proteinuria occasionally persists, suggesting that tubulointerstitial damages persist even in dogs responsive to treatments.

Keywords	Canine Leishmaniasis, Proteinuria, Chronic kidney disease, Renal biomarker
Manuscript category	Biochemistry
Corresponding Author	Saverio Paltrinieri
Corresponding Author's Institution	University of Milan
Order of Authors	Saverio Paltrinieri, Giulia Mangiagalli, Fabrizio Ibba
Suggested reviewers	Anna Winnicka, Eric Zini, Mary Nabity

Submission Files Included in this PDF

File Name [File Type]

RVSC_2017_768-R1 cover letter.docx [Cover Letter]

RVSC_2017_768 response to reviewers.docx [Response to Reviewers]

RVSC_2017_768-R1 highlights.docx [Highlights]

RVSC_2017_768-R1.docx [Manuscript File]

RVSC_2017_768-R1 figure 1.tif [Figure]

RVSC_2017_768-R1 table.docx [Table]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Research Data Related to this Submission

There are no linked research data sets for this submission. The following reason is given: raw data already tabled in the manuscript



UNIVERSITÀ DEGLI STUDI DI MILANO
DIPARTIMENTO DI MEDICINA VETERINARIA

Milano Jan 15th 2017

Dear Editor

Herewith attached you can find the revised version of the manuscript: “Use of urinary γ -glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with leishmaniasis treated with N-methylglucamine antimoniate”, to be considered for publication.

The manuscript has been revised according to the comments of the Reviewer

A revision note, that reports in red the responses to the reviewer comments has been uploaded along with the manuscript

Please feel free to contact me for any possible enquiry regarding this manuscript


Saverio Paltrinieri

Prof. Saverio Paltrinieri
Dipartimento di Medicina Veterinaria
Università di Milano, Via Celoria 10 - 20133 Milano, Italy
Tel: ++39 02 50318103
Fax: ++39 02 50318095
e-mail: saverio.paltrinieri@unimi.it

RVSC_2017_768

Title: Use of urinary gamma-glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with leishmaniasis treated with N-methylglucamine antimoniate

Comments from the editors and reviewers:

-Reviewer 1

We were not able to find comments from reviewer 1. We would be happy to make further changes if comments from Reviewer 1 are provided

-Reviewer 2

Line 24: I suggest to use the term tubular damage than tubular proteinuria

The term "tubular proteinuria" has been replaced where indicated by the reviewer. We did not understand whether the recommendation of the reviewer was to replace the term only at line 24 or throughout the manuscript. For now we have only replaced this term where requested but we would be happy to do it in other parts of the manuscript, if requested.

Line 42: symptoms are descriptive terms used in human medicine where subjective perception occurs

"symptoms" has been replaced by "clinical signs"

Line 98: it is unclear how the authors selected the 10 dogs with Leishmaniasis

This information has been added to the text and the sentences at the beginning of the material and methods section have been modified accordingly

Line 101: 8 males more 3 females = 11 dogs not ten dogs as author described before

We are sorry for this mistake. The error now has been corrected

Line 102: definition of range is not correct. Minimum and maximum is not the range

The paragraph has been modified and the sentence corrected as requested

Line 104: see comment of line 42

"symptoms" has been replaced by "clinical signs"

Line 125-127 It should be better declare numerical aperture of the microscope lens too

This information has been added to the text

Line 131 why authors measure specific gravity by not validated device

The accuracy of the device used in this study was preliminarily assessed in comparison with a validated instrument. This information has now been added to the manuscript

Line 144: there is a "the" more

One of the two "the" has been removed

147: it should be declared better the statistical software (years for example)

Details of the software version have been provided

Line 148: $p < 0.05$ vs $P < 0.05$

We assume that the recommendation of the reviewer is to replace "P" with "p". This change has been done (also in the legend of figure 1).

Line 220: why the authors think that the low number of cases represents a limitation of the study

The low number of cases may reduce the statistical relevance of the results. This explanation has now been added to the manuscript

General comment: Referring to the quotations in lines 43-44-48-51-56-78, it would be more elegant to mention the authors who first highlighted that data

We do not understand how the Reviewer recommends to redistribute the citations within the text. In the current forms citations have been added where appropriate (e.g. where the finding described by each Author) are cited in the text. However, if the Reviewer or the editor prefer a different format for citations we would be happy to modify the citations or to replace them with other citations recommended by the Reviewer

1 **Use of urinary γ -glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with**
2 **leishmaniasis treated with N-methylglucamine antimoniate**

3

4 Saverio Paltrinieri, DVM, PhD, Dipl. ECVCP^{a,b}

5 Giulia Mangiagalli, DVM^a

6 Fabrizio Ibba, DVM, PhD^{a,c}

7

- 8 - Urinary GGT activity may be high in leishmaniotic dogs, due to a tubular injury.
- 9 - The high GGT/CU may depend also on a functional impairment of tubular cells
- 10 - Leishmanicidal treatments may restore tubular function and decrease the GGT/CU
- 11 - In this study the GGT/UC ratio decreased in 8/10 treated dogs
- 12 - The GGT/UC ratio may differentiate dogs with permanent or transient tubular injury

1
2
3
4 1 **Use of urinary γ -glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with**
5
6 2 **leishmaniasis treated with N-methylglucamine antimoniate**
7
8
9 3

10
11 4 Saverio Paltrinieri, DVM, PhD, Dipl. ECVCP^{a,b}
12

13
14 5 Giulia Mangiagalli, DVM^a
15

16
17 6 Fabrizio Ibba, DVM, PhD^{a,c}
18
19

20 7
21
22

23 8
24
25

26 9 ^aDepartment of Veterinary Medicine, University of Milan, Milan, Italy
27

28
29 10 ^bVeterinary teaching hospital, University of Milan
30

31
32 11 ^cVeterinary Clinic Poggio dei Pini, Capoterra, Cagliari, Italy
33
34

35 12
36
37

38 13
39

40 14 Corresponding author
41

42
43 15 Prof. Saverio Paltrinieri, DVM, PhD, Dipl ECVCP
44

45
46 16 e-mail: saverio.paltrinieri@unimi.it
47

48
49 17 Phone: 0039-02-50318103
50

51
52 18 Fax: 0039-02-50318095
53
54
55
56
57
58
59

60
61
62 19 **Abstract**
63
64

65 20 The aim of this study was to assess if the coupled analysis of the urinary protein to creatinine (UPC)
66
67 21 ratio and of the GGT/UC ratio (the ratio between urinary γ -glutamyl transferase activity and urinary
68
69 22 creatinine) may be used in treated leishmaniotic dogs to differentiate dogs with transient impairment
70
71
72 23 of tubular function from dogs with persistent tubular damage.
73

74
75 24 To this aim, 40 urine from 10 proteinuric and leishmaniotic dogs that at the first visit had high
76
77 25 GGT/UC ratio, consistent with tubular proteinuria damage, were collected and analyzed before
78
79 26 treatments and 2, 4 and 6 weeks after treatment with N-methylglucamine antimoniate and allopurinol.
80

81
82 27 Compared with pre-treatment values, at the end of the study period the UPC ratio decreased only in
83
84 28 5/10 dogs, which, however, were still proteinuric or borderline proteinuric. Conversely, the GGT/UC
85
86 29 ratio decreased in 8/10 dogs and in 3 of them the values at the end of the study period were below the
87
88 30 threshold consistent with tubular proteinuria. The GGT/UC values at 6 weeks was significantly lower
89
90 31 than before treatment. However, transient increases were frequent for both the analytes.
91

92 32 These results indicate that in most of the dogs that remain proteinuric after treatment, likely due to
93
94 33 the persistent glomerular damage, the GGT/UC ratio tends to normalize. This suggests that in these
95
96 34 dogs tubular proteinuria at admission depends on functional impairment of tubular cells likely due to
97
98
99 35 the overflow of proteins from damaged glomeruli. However, tubular proteinuria occasionally persists,
100
101 36 suggesting that tubulointerstitial damages persist even in dogs responsive to treatments.
102

103 37
104
105
106 38 **Keywords:** Canine Leishmaniasis; Proteinuria; Chronic kidney disease; Renal biomarker
107
108

109 39
110

111 40
112
113
114
115
116
117
118

119
120
121 **41 Introduction**
122
123

124 42 Canine leishmaniasis is characterized by a broad spectrum of ~~symptoms~~clinical signs, due to a variety
125
126 43 of lesions in different organs (Paltrinieri et al., 2016). Renal lesions may induce a life-threatening
127
128 44 chronic renal disease (CKD) in affected dogs (Koutinas and Koutinas 2014). Leishmaniotic dogs may
129
130 45 develop a proteinuric nephropathy that starts with an immune-mediated glomerulonephritis
131
132 46 characterized by glomerular proteinuria that in turn induces functional or structural lesions in tubular
133
134 47 cells. Therefore, mixed proteinuria is considered the most frequent finding in the advanced stages of
135
136 48 canine leishmaniasis (Zatelli et al., 2003). Conversely, leishmanicidal treatments should decrease
137
138 49 immuno-complex formation and deposition. This may modify the composition of urinary proteins
139
140 50 over time.
141
142

143 51 The presence and magnitude of proteinuria is considered a risk factor for the progression of renal
144
145 52 disease (Jacob et al., 2005) and both the guidelines released by the American College of Veterinary
146
147 53 Internal Medicine (Lees et al., 2005) and by the International Renal Interest Society (IRIS Canine GN
148
149 54 Study Group, Diagnosis Subgroup, 2013), recommend to monitor proteinuria in dogs at risk for
150
151 55 development of glomerular disease and to set up pharmacological treatments as soon as the dog
152
153 56 became proteinuric. Moreover, the localization of proteinuria (glomerular vs tubular or both) should
154
155 57 be a mandatory step in the investigation of canine proteinuria (Lees et al., 2005). Renal biopsy is the
156
157 58 only reliable tool for localizing the renal lesions (Lees et al., 2005). However, the invasiveness of the
158
159 59 technique limits its use in the clinical practice, especially when analyses should be repeated over time.
160
161

162 60 Therefore, renal biopsy is recommended only in dogs not responding to treatments or in case of a
163
164 61 rapid progression of kidney disease (IRIS Canine GN Study Group Diagnosis Subgroup, 2013).
165
166 62 Sodium dodecyl-sulphate polyacrilamide gel electrophoresis (SDS-PAGE) or SDS agarose gel
167
168 63 electrophoresis (SDS-AGE) differentiate the origin of proteinuria based on the molecular weight
169
170 64 (MW) of urinary proteins (Schultze and Jensen 1998). The SDS techniques correlate with the results
171
172 65 of renal biopsy, but their specificity is low (Brown et al., 2010; Zini et al., 2004). Moreover, although
173
174
175
176
177

178
179
180 66 less invasive than renal biopsy, these techniques are not available in routine practices that use in-
181
182 67 house analyzers. Recently, the measurement of urinary GGT, with the same analytical principle used
183
184 68 on most in-house analyzers, has been proposed as a tool to detect tubular proteinuria in leishmaniotic
185
186 69 dogs (Palacio et al., 1997), on which it may predict the results of SDS-AGE (Ibba et al., 2016). The
187
188 70 enzyme γ -glutamyl transferase (GGT) is expressed in renal tubular cells (Braun et al., 1983). After
189
190 71 detachment of the enzyme from the damaged tubular cells, GGT may be found in urine, where its
191
192 72 activity is not influenced by serum levels of GGT since it does not undergo glomerular filtration and
193
194 73 GGT activity may be measured using the same analytical principle used in many in-clinic analyzers.
195
196 74 Therefore, increases in the ratio between urinary GGT and urinary creatinine (GGT/UC ratio) may
197
198 75 early detect renal tubular dysfunction or damage (Brunker et al., 2009; Uechi et al., 1994) pending
199
200 76 that GGT activity is measured just after sampling, to avoid storage artifacts (Flandrois et al., 1989).
201
202 77 Based on what reported above, monitoring the magnitude of proteinuria is a milestone of the
203
204 78 clinicopathological follow-up in the leishmaniotic patient either at first diagnosis or after treatment
205
206 79 (Roura et al., 2013). Changes of protein to creatinine (UPC) ratio in dogs receiving N-
207
208 80 methylglucamine antimoniate and allopurinol or allopurinol alone have been already investigated
209
210 81 (Pardo-Marin et al., 2017; Pierantozzi et al., 2013; Plevraki et al., 2006). Conversely, to our
211
212 82 knowledge, only one study investigated separately the possible changes of urinary markers of
213
214 83 glomerular or tubular injury during treatment (Pardo-Marin et al., 2017). However, this latter study
215
216 84 was focused on a short post-treatment follow up, and provided contrasting results regarding
217
218 85 biomarkers of tubular damage. A more reliable information would be useful in patient's management
219
220 86 since the identification of a persistent tubular damage may indicate the progression of canine
221
222 87 leishmaniasis while a regression of tubular proteinuria may differentiate dogs with irreversible
223
224 88 structural tubular changes from those that before treatment had a functional proteinuria due to the
225
226 89 saturation of tubular cells subsequent to the overflow of glomerular proteins.
227
228 90 Hence, the aims of this study were to assess whether the simultaneous analysis of UPC and GGT/UC
229
230 91 ratio might provide additional information compared with the traditional approach based on the
231
232
233
234
235
236

237
238
239 92 evaluation of the UPC ratio alone in leishmaniotic dogs that had tubular proteinuria at admission and
240
241 93 successfully responded to treatments with N-methylglucamine antimoniate and allopurinol.
242
243

244 94
245
246

247 95 **Material and methods**

248
249

250 96
251
252

253 97 *Animals and study design*

254
255

256 98 This study was performed on 40 urine samples from 10 leishmaniotic dogs aged 2 to 11 years
257
258 99 (median: 6 years), randomly selected among those referred to our institution for diagnosing, treating
259
260 100 and monitoring leishmaniasis and that at the time of first diagnosis were in IRIS stage I (creatinine
261
262 101 <1.5 mg/dL). The dogs ~~that~~ were proteinuric (n=9) or borderline proteinuric (n=1) and had a
263
264 102 GGT/CU higher than 0.81, i.e. the threshold consistent with a tubular component of proteinuria (Ibba
265
266 103 et al., 2016). The study group included 6 crossbreed dogs, 1 Pitbull, 1 German shepherd, 1 Epagneul
267
268 104 Breton, 1 English Setter. Eight Seven dogs were males, 3 were females. The age range was 2-11 years
269
270
271 105 (median: 6 years).
272
273

274 106 According to the current guidelines for diagnosis and classification of canine leishmaniasis
275
276 107 (Paltrinieri et al., 2010), the diagnosis was based on the presence of typical symptoms-clinical signs
277
278 108 (e.g. cutaneous lesions, enlarged lymph nodes) and/or laboratory abnormalities (anemia,
279
280 109 hyperproteinemia with inverted albumin:globulin ratio and polyclonal gammopathy) and on the
281
282 110 detection of amastigotes in cytological specimens from lymph nodes with reactive
283
284 111 (pyogranulomatous) lymphadenopathy. Therefore, serology was not performed in all cases, since,
285
286 112 based on the guidelines mentioned above, the detection of intralesional parasites is sufficient to
287
288 113 classify the dogs as sick.
289
290
291
292
293
294
295

296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

114 Dogs were treated with N-methylglucamine antimoniate (Glucantime, Merial Italia S.p.A., Milan,
115 Italy; 100 mg/kg, SC once a day for 30 days) and allopurinol (Zyloric, Teofarma S.r.l. Pavia, Italy;
116 10 mg/kg, orally twice a day for 6 months), as recommended by the current guidelines for treatment
117 of canine leishmaniasis (Oliva et al., 2010).

118 Urine samples were collected, under informed consent by the owners, by cystocentesis at the time
119 of first diagnosis, before drugs administration, and after 2, 4 and 6 weeks after the beginning of the
120 leishmanicidal treatment. According to the regulations of our Institution, when an informed consent
121 is obtained from the owner, a formal approval from the Ethical Committee is not required if samples
122 are performed for diagnostic or monitoring purposes, as in this case (EC decision 29 Oct 2012,
123 renewed with the protocol n° 02-2016).

125 *Urinalysis and biochemical tests*

126 Five millilitres of each sample have been centrifuged at 500 g for 5 mins. Then, 4.5 mLs of each
127 supernatant were removed and aliquoted in other tubes.

128 The remaining 0.5 mLs of each supernatant were used to resuspend the sediment and 50 µLs of the
129 resuspended sediment were examined microscopically at 400× magnification (numerical aperture of
130 the microscope lens = 22), to count the mean number of red blood cells (RBCs) and white blood cells
131 (WBCs) per high power field (hpf) and to exclude that samples had an active sediment (i.e. a sediment
132 characterized by bacteriuria, presence of casts, or with more than 5 RBCs, WBCs, or epithelial
133 cells/hpf).

134 One aliquot of the supernatant was used to measure GGT activity with the method proposed by Szasz
135 (1969) in an automated spectrophotometer (Mindray BC-120, Shenzhen Mindray Biomedical, Shenzhen,
136 China) and to determine the urinary specific gravity (USG) using a manual refractometer (HR-160,
137 Optika SRL, Ponteranica, Bergamo, Italy) whose accuracy was determined in house by comparing
138 the results with those of a refractometer used in a previous study (Rossi et al., 2012). The other

355
356
357 139 aliquots were frozen (-20°C) to determine the concentration of urinary proteins (UP) and urinary
358
359 140 creatinine (UC) within one month from sampling.

361 141 Specifically, UPs were measured after thawing with an automated spectrophotometer (Cobas Mira,
362
363 Roche Diagnostics, Basel, Switzerland) using pyrogallol red (Total Proteins High Sensitivity, Ben
364 142 Biochemical Enterprise, Milan, Italy): samples with UPs >250 mg/dL were manually diluted 1:5 with
365
366 143 distilled water and re-analysed to avoid inaccurate measurement for values outside the linearity of the
367
368 144 method. The UC was measured with a modified Jaffe method (Real Time Diagnostic Systems,
369
370 145 Viterbo, Italy). Samples were manually diluted 1:20 with distilled water to fit the linearity of the
371
372 146 method (Rossi et al., 2012).

373
374 147 The UPC ratio and the GGT/UC ratio were then calculated
375
376 148

377 149 378 379 380 381 150 *Statistical analysis* 382 383

384 151 Results regarding the ~~the~~ GGT/UC ratio recorded in sequential samplings were compared to each
385
386 152 other using a non parametric ANOVA for paired data (Friedmann test), followed by a Bonferroni test
387
388 to compare the results recorded after treatment with the baseline values (i.e. the values recorded at
389 153 admission, before any treatment). Statistical analyses were run in a specific software ([Analyse-it](#)
390
391 154 [version 2.21](#), Analyse-it Software Ltd, Leeds, UK) and the level of significance was set at $P_p < 0.05$
392
393 155
394
395 156

396 397 157 **Results** 398

399 158 All the dogs enrolled in the study remained in IRIS stage I during the study period and their clinical
400
401 159 condition improved in 1-3 weeks of treatment.

402
403 160 Results regarding urinary findings are reported in table 1.

404
405 161 Compared with values recorded at admission, at the end of the study period the UPC ratio decreased
406
407 162 in 5/10 dogs, and increased in 5/10 dogs despite the amelioration of clinical signs. In 3 out of these
408
409 163 latter 5 dogs the increase was severe (the UPC values increased more than 2 times). Three out of the
410
411
412
413

414
415
416 164 nine proteinuric dogs became borderline proteinuric at the end of the study period while the borderline
417
418 165 proteinuric dog became frankly proteinuric. Due to this variable behavior, no significant differences
419
420
421 166 were found between the UPC values of sequential samplings (figure 1).

422
423 167 Compared with the pre-treatment sample, at the end of the study period the GGT/CU ratio decreased
424
425 168 in 8/10, remained substantially unchanged in 1/10 dogs and increased in 1/10 dogs. Moreover, in 3/10
426
427 169 dogs values at the end of the study period the GGT/UC ratio decreased below the threshold consistent
428
429 170 with tubular proteinuria (0.81) and in one out of these 3 dogs the decrease below this threshold
430
431 171 occurred very early, at the second week of treatment. On a statistical point of view, values at 6 weeks
432
433 172 were significantly lower than before treatment (figure 1).

434
435 173 However, transient increases of both the UPC and the GGT/UC ratio were found also in those cases
436
437
438 174 on which the value at the end of the study period finally decreased.

440 175 441 442 176 **Discussion**

443
444 177 The early phase of canine leishmaniasis is characterized by the progressive development of an
445
446 178 immune-mediated glomerulopathy that induces a proteinuric nephropathy. The passage of proteins
447
448 179 through the glomerular barrier may induce functional tubular impairment, that may theoretically be
449
450 180 restored when the overflow of proteins decreases after anti-leishmaniotic treatment, or structural
451
452 181 damages of tubular cells, that may persist despite the improvement of clinical signs after treatments.

453
454 182 Hence, this study was designed to assess whether in leishmaniotic dogs with changes consistent with
455
456
457 183 tubular proteinuria at first visit that showed an amelioration of clinical signs after conventional
458
459 184 treatments, the simultaneous evaluation of the UPC ratio and the GGT/UC may provide additional
460
461 185 information, compared with the recommended approach (Roura et al., 2013), that includes only the
462
463 186 evaluation of the UPC. The addition of the GGT/UC may in fact differentiate dogs with transient
464
465 187 impairment of tubular functions from those with permanent tubular damages.

466
467 188 The GGT/UC has been chosen as an alternative method to investigate the presence of tubular damage
468
469 189 since GGT may be released from the membranes of damaged tubular cells (Brunker et al., 2009) and
470

473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531

190 its measurement in urine is less invasive than renal biopsy, that is the gold standard for assessing
191 tubular damage (IRIS Canine GN Study Group, Diagnosis Subgroup, 2013), and is cheaper and easier
192 to perform in house in routine practice than SDS electrophoretic techniques, that well correlate with
193 results of renal biopsies (Brown et al., 2010; Zini et al., 2004) or than analytes that have been more
194 recently proposed for the investigation of renal function such as retinol binding protein (RBP) or
195 Neutrophil gelatinase-associated lipocalin (NGAL) (Hokamp et al., 2016) .

196 Since storage, either at 4°C or at -20°C, may inactivate the enzyme and provide false negative results
197 (Flandrois et al., 1989), only samples on which the activity of GGT was measured soon after sampling
198 and centrifugation were included in the study.

199 The results of this study demonstrated that both the markers showed transiently increased during the
200 study period, as already demonstrated in previous studies on proteinuria (Pierantozzi et al., 2013;
201 Plevraki et al., 2006), likely depending on the release of antigens after the death of the parasite, with
202 subsequent temporary worsening or immune-complex glomerulonephritis, that induces the increase
203 of the UPC, and a subsequent overflow of proteins that it may be responsible for a transient functional
204 impairment of tubular functions.

205 Apart from these fluctuations, the UPC decreased, at the end of the study period, only in half of the
206 dogs, on which, however, values remained in the proteinuric or borderline proteinuric range, and no
207 significant differences compared with values recorded at admission were found. This is not surprising,
208 since significant differences of the UPC may require up to 8 weeks after treatment (Pierantozzi et al.,
209 2013), and in most cases dogs were still proteinuric also in previous longitudinal studies (Pierantozzi
210 et al., 2013; Plevraki et al., 2006), likely because the immune-mediated glomerulonephritis that
211 characterizes canine leishmaniasis may induce permanent and non reversible glomerular damage
212 (Koutinas and Koutinas, 2014)

213 Conversely, the GGT/UC decreased in the large majority of dogs, its decrease was statistically
214 significant, and values decreased below the threshold consistent with tubular damage in 3 dogs,
215 suggesting that in most cases the tubular proteins detectable at admission were likely due to a

532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590

216 functional impairment of tubular cells due to the overflow of proteins associated with glomerular
217 damages and that this impairment disappear when the overflow of proteins decreases after treatment.
218 This seems to contrast with a previous study on which no significant differences in the GGT/UC were
219 found after 4 weeks of treatment compared with the pre-treatment levels (Pardo-Marin et al., 2017).
220 However, in the cited study urinary GGT was measured in frozen urine and results may therefore
221 have been biased by the storage artifacts mentioned above (Flandrois et al., 1989). This may explain
222 why in the former study the GGT/UC did not decrease after treatment as the other tubular markers
223 included in the study. Conversely, in the current study only in a minority of dogs the GGT/CU did
224 not change at the end of the study period compared with pre-treatment values. This suggests that in a
225 few dogs the tubulointerstitial damage persists after treatment, as evidenced in some studies based on
226 histopathology (Aresu et al., 2013).

227 This study has two main limitations: one is the low number of cases, that may reduce the statistical
228 relevance of the results, due to the difficulties to obtain the whole series of samples during the follow
229 up, in turn depending on a poor compliance of the owners. However, this allowed us to perform the
230 study on a population with standardized inclusion criteria and time samplings. The second limitation
231 is the lack of histopathologic findings, that cannot be repeatedly performed in field conditions for
232 obvious ethical reasons,

233 In conclusion, this study demonstrates that the coupled analysis of both the UPC and the GGT/UC
234 ratio may provide additional information compared with the simple analysis of the UPC since this
235 latter may remain in the proteinuric range due to the persistency of glomerular lesions, while the
236 normalization of the GGT/UC may differentiate the dogs that at the first visit had a functional
237 impairment of tubular cells, from those on which tubulointerstitial damages persist despite the
238 normalization of clinical signs, on which the GGT/UC remain high. Despite the limitations mentioned
239 above, these results are encouraging to design future studies, eventually based on longer observation
240 times or on the comparison with the results of renal biopsies. Moreover, it would be interesting in the

591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649

241 future to assess whether the non invasive technique investigated in the current study may provide
242 relevant clinical information on the management of dogs that do not respond to treatments.

244 **Acknowledgments**

245 No specific funds were used to support this study

247 **Conflict of interest**

248 The Authors do not have any conflict of interest potentially interfering with the results of this study

250 **References**

- 251
252 1. Aresu, L., Benali, S., Ferro, S., Vittone, V., Gallo, E., Brovida, C., Castagnaro, M., 2013.
253 Light and electron microscopic analysis of consecutive renal biopsy specimens from
254 leishmania-seropositive dogs. *Vet. Pathol.* 50, 753-760.
- 255 2. Braun, J.P., Benard, P., Burgat, V., Rico, A.G., 1983. Gamma glutamyl transferase in
256 domestic animals. *Vet. Res. Comm.* 6, 77-90.
- 257 3. Brown, J.S., Nabity, M.B., Brock, R., 2010. Comparison of urine sodium dodecyl sulphate
258 polyacrylamide gel electrophoresis (SDS-PAGE) with renal histological findings and
259 clinicopathologic data in dogs with renal diseases. *Vet. Clin. Pathol.* 39, 556
- 260 4. Brunker, J.D., Ponzio, N.M., Payton, M.E., 2009. Indices of urine N-acetyl-beta-D-
261 glucosaminidase and gamma-glutamyl transpeptidase activities in clinically normal adult
262 dogs. *Am. J. Vet. Res.* 70, 297-301.
- 263 5. Flandrois, C., Lahet, C., Feldmann, D., Maire, I., Aymard, P., Mathieu, M., 1989.
264 Optimization of the determination in urine of alanine aminopeptidase, gamma-
265 glutamyltransferase and N acetyl-beta-D-glucosaminidase. *Ann. Biol. Clin. (Paris)* 47, 252-
266 260.

- 650
651
652 267
653
654 268
655
656
657 269
658
659 270
660
661 271
662
663 272
664
665 273
666
667 274
668
669 275
670
671 276
672
673
674 277
675
676 278
677
678 279
679
680 280
681
682 281
683
684 282
685
686 283
687
688 284
689
690 285
691
692
693 286
694
695 287
696
697 288
698
699 289
700
701 290
702
703 291
704
705 292
706
707
708
6. Hokamp, J.A., Cianciolo, R.E., Boggess, M., Lees, G.E., Benali, S.L., Kovarsky, M., Nability M.B., 2016. Correlation of urine and serum biomarkers with renal damage and survival in dogs with naturally occurring proteinuric chronic kidney disease. *J Vet Intern Med* 30, 591–601.
 7. Ibba, F., Mangiagalli, G., Paltrinieri, S., 2016. Urinary gamma-glutamyl transferase (GGT) as a marker of tubular proteinuria in dogs with canine leishmaniasis, using sodium dodecylsulphate (SDS) electrophoresis as a reference metho. *Vet. J.* 210, 88-91.
 8. IRIS Canine GN Study Group Diagnosis Subgroup, Littman, M.P., Daminet, S., Grauer, G.F., Lees, G.E., van Dongen, A.M., 2013. Consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease. *J. Vet. Intern. Med.* 27 Suppl 1, S19-S26.
 9. Jacob, F., Polzin, D.J., Osborne, C.A., Neaton, J.D., Kirk, C.A., Allen, T.A., Swanson, L.L., 2005. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. *J. Am. Vet. Med. Assoc.* 226, 393-400.
 10. Koutinas, A.F., Koutinas, C.K., 2014. Pathologic mechanisms underlying the clinical findings in canine leishmaniosis due to *Leishmania infantum/chagasi*. *Vet. Pathol.* 51, 527-538.
 11. Lees, G.E., Brown, S.A., Elliot, J., Grauer, G.F., Vaden, S.L., 2005. Assessment and menagement of proteinuria in dogs and cats. *J. Vet. Intern. Med.* 19, 377-385.
 12. Oliva, G., Roura, X., Crotti, A., Maroli, M., Castagnaro, M., Gradoni, L., Lubas, G., Paltrinieri, S., Zatelli, A., Zini, E., 2010. Guidelines for treatment of leishmaniasis in dogs. *J. Am. Vet. Med. Assoc.* 236, 1200-1206.
 13. Palacio, J., Liste, F., Gascon, M., 1997. Enzymuria as an index of renal damage in canine leishmaniasis. *Vet. Rec.* 140, 477-480.
 14. Paltrinieri, S., Solano-Gallego, L., Fondati, A., Lubas, G., Gradoni, L., Castagnaro, M., Crotti, A., Maroli, M., Oliva, G., Roura, X., Zanelli, A., Zini, E., 2010. Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. *J. Am. Vet. Med. Assoc.* 236, 1184-1191.

709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767

293 15. Palltrinieri, S., Gradoni, L., Roura, X., Zatelli, A., Zini, E., 2016. Laboratory tests for
294 diagnosing and monitoring canine leishmaniasis. *Vet. Clin. Pathol.* 45, 552-578.

295 16. Pardo-Marin, L., Martínez-Subiela, S., Pastor, J., Tvarijonaviciute, A., Garcia-Martinez, J.D.,
296 Segarra, S., Cerón, J.J., 2017. Evaluation of various biomarkers for kidney monitoring during
297 canine leishmaniosis treatment. *BMC Vet. Res.* 13, 31. Doi: 10.1186/s12917-017-0956-0.

298 17. Pierantozzi, M., Roura, X., Paltrinieri, S., Poggi, M., Zatelli, A., 2013. Variation of proteinuria
299 in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a
300 retrospective study. *J. Am. Anim. Hosp. Assoc.* 49, 231-236.

301 18. Plevraki, K., Koutinas, A.F., Kaldrymidou, H., Roumpies, N., Papazoglus, L.G.,
302 Saridomichelakis, M.N., Savva, S.L., Leondides, L., 2006. Effects of allopurinol treatment on
303 the progression of chronic nephritis in canine leishmaniosis (*Leishmania infantum*). *J. Vet.*
304 *Intern. Med.* 20, 228-233.

305 19. Rossi, G., Giori, L., Campagnola, S., Zatelli, A., Zini, E., Paltrinieri, S., 2012. Evaluation of
306 factors that affect analytic variability of urine protein-to-creatinine ratio determination in
307 dogs. *Am. J. Vet. Res.* 73, 779-788.

308 20. Roura, X., Fondati, A., Lubas, G., Gradoni, L., Maroli, M., Oliva, G., Paltrinieri, S., Zatelli,
309 A., Zini, E., 2013. Prognosis and monitoring of leishmaniasis in dogs: A working group report.
310 *Vet. J.* 198, 43-47.

311 21. Schultze, A.E., Jensen, R.K., 1998. Sodium dodecyl sulfate polyacrylamide gel
312 electrophoresis of canine urinary proteins for the analysis and differentiation of tubular and
313 glomerular diseases. *Vet. Clin. Pathol.* 18, 93-97.

314 22. Szasz, G., 1969. A kinetic photometric method for serum γ -glutamyltransferase. *J. Clin.*
315 *Chem.* 15, 124-136.

316 23. Uechi, M., Nogami, Y., Terui, H., Nakayama, T., Ishikawa, R., Wakao, Y., Takahashi, M.,
317 1994. Evaluation of urinary enzymes in dogs with early renal disorder. *J. Vet. Med. Sci.* 56,
318 555-556.

768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826

319 24. Zatelli, A., Borgarelli, M., Santilli, R., Bonfanti, U., Nigrisoli, E., Zanatta, R., Tarducci, A.,
320 Guarraci, A., 2003. Glomerular lesions in dogs infected with Leishmania organisms. Am. J.
321 Vet. Res. 64, 558-561.

322 25. Zini, E., Bonfanti, U., Zatelli, A., 2004. Diagnostic relevance of qualitative proteinuria
323 evaluated by use of sodium dodecyl sulfate-agarose gel electrophoreis and comparison with
324 renal histologic findings in dogs. Am. J. Vet. Res. 65, 964-971.

827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885

Figure captions

Figure 1: Data distribution and statistical analysis of results regarding the UPC ratio (A) and the GGT/UC ratio (B) recorded over time. The boxes indicate the I–III interquartile interval, the horizontal line corresponds to the median, vertical lines are the limits of outlier distribution according to the Tukey rule. Near outliers are indicated by the symbols “x” and far outliers with asterisks outside the boxes. The bolded asterisk within the boxes indicates a statistical difference ($p < 0.05$) compared with the baseline value





Table 1: Results recorded in the all the samples included in this study

Dog n	Before treatment			2 weeks			4 weeks			6 weeks		
	UPC	IRIS	GGT	UPC	IRIS	GGT	UPC	IRIS	GGT	UPC	IRIS	GGT
1	1.52	P	3.3	0.25	BP	1.42	0.27	BP	1.81	0.28	BP	0.94
2	1.04	P	1.04	0.79	P	0.89	2.30	P	2.54	1.36	P	1.17
3	1.45	P	2.48	1.31	P	2.99	1.23	P	7.01	0.76	P	3.18
4	1.57	P	3.94	0.81	P	4.97	0.35	BP	3.11	2.13	P	0.81
5	0.84	P	1.85	1.42	P	1.23	0.79	P	0.91	1.03	P	1.11
6	0.36	BP	0.85	0.63	P	0.75	1.74	P	1.01	2.10	P	0.69
7	2.36	P	0.91	1.18	P	0.49	0.05	NP	0.28	0.23	BP	0.15
8	1.89	P	0.81	1.47	P	0.77	1.40	P	0.52	1.21	P	0.61
9	3.11	P	2.15	0.34	BP	1.63	3.73	P	1.06	10.76	P	1.45
10	3.03	P	2.46	4.14	P	0.35	6.08	P	0.69	0.23	BP	0.09

BP = borderline proteinuric (UPC ratio between 0.2 and 0.5); GGT/CU = γ -glutamyl transferase/urinary creatinine ratio; IRIS = staging of proteinuria according to the International Renal Interest Society (IRIS); NP = non proteinuric (UPC ratio<0.2); P = proteinuric (UPC ratio >0.50); UPC = urinary protein to creatinine ratio